2 unchanged sentences
10b5-1(c) or may represent a non-Rule 10b5-1 trading arrangement under the Exchange Act.
−Removed: During the quarter ended March 31, 2024, no such plans or other arrangements were adopted or terminated .
+Added: During the quarter ended June 30, 2024, no such plans or other arrangements were adopted or terminated .
See the Exhibit Index immediately following the signature page of this Quarterly Report on Form 10-Q.
1 unchanged sentence
ADMA Biologics, Inc.
−Removed: President, Chief Executive Officer and Interim
+Added: August 8, 2024
+Added: President and Chief Executive Officer
+Added: August 8, 2024
+Added: /s/ Brad Tade
Chief Financial Officer
1 unchanged sentence
Exhibit Number
−Removed: Consulting Services Agreement, dated as of February 27, 2024, by and between ADMA Biologics, Inc.
−Removed: and Brian Lenz (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on
−Removed: February 28, 2024).
−Removed: Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
−Removed: Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C.
+Added: Second Amended and Restated Bylaws of ADMA Biologics, Inc.
+Added: (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on June 28, 2024).
+Added: Employment Agreement, dated April 1, 2024, by and between ADMA Biologics, Inc.
+Added: and Kaitlin Kestenberg (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on April 2, 2024).
+Added: Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
+Added: Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
+Added: Certification of Principal Executive Officer pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: The following materials from ADMA Biologics, Inc.’s Form 10-Q for the quarter ended March 31, 2024, formatted in Extensible Business Reporting Language (XBRL):
−Removed: (i) Condensed Consolidated Balance Sheets as of March
−Removed: 31, 2024 (Unaudited) and December 31, 2023, (ii) Condensed Consolidated Statements of Operations (Unaudited) for the three months ended March 31, 2024 and 2023, (iii) Condensed Consolidated Statements of Changes in Stockholders’ Equity
−Removed: (Unaudited) for the three months ended March 31, 2024 and 2023, (iv) Condensed Consolidated Statements of Cash Flows (Unaudited) for the three months ended March 31, 2024 and 2023, and (v) Notes to (Unaudited) Condensed Consolidated
−Removed: Financial Statements.
+Added: Certification of Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
+Added: The following materials from ADMA Biologics, Inc.’s Form 10-Q for the quarter ended June 30, 2024, formatted in Extensible Business Reporting Language (XBRL):
+Added: (i) Condensed Consolidated Balance Sheets as of June
+Added: 30, 2024 (Unaudited) and December 31, 2023, (ii) Condensed Consolidated Statements of Operations (Unaudited) for the three and six months ended June 30, 2024 and 2023, (iii) Condensed Consolidated Statements of Changes in Stockholders'
+Added: Equity (Unaudited) for the three and six months ended June 30, 2024 and 2023, (iv) Condensed Consolidated Statements of Cash Flows (Unaudited) for the six months ended June 30, 2024 and 2023, and (v) Notes to (Unaudited) Condensed
+Added: Consolidated Financial Statements.
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
* Filed herewith.
−Removed: ** In accordance with SEC Release 33-8238, Exhibit 32.1 is being furnished and not filed.
+Added: ** In accordance with SEC Release 33-8238, Exhibits 32.1 and 32.2 are being furnished and not filed.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.